Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 572
- Registration Number
- NCT00115570
- Locations
- 🇺🇸
Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT00097071
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
- Conditions
- First Posted Date
- 2003-10-24
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 378
- Registration Number
- NCT00071448
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.